AI and Cancer Research ── Cancer biology ── 2026-11-13
Cancer molecular biology and AI
- Abstract
Message Artificial intelligence (AI) has proven effective in assessing bowel preparation adequacy, but its role in guiding personalised laxative dosing is untested. In this prospective, multicentre, endoscopist-masked randomised trial, 1650 participants were assigned to AI-assisted or conventional groups using self-evaluation (SE) by patients during a 3 L split-dose polyethylene glycol (PEG) regimen. The AI group used significantly less PEG (mean difference –496.1 mL; p<0.001) while maintaining similar bowel cleanliness, polyp detection rates (PDR) and withdrawal times. Right colon scores were slightly higher, with less nausea and bloating reported in the AI group. AI-assisted assessment (AIA) offers an effective personalised approach to colonoscopy and warrants evaluation with other regimens. In more detail Colonoscopy plays a vital role in early detection of colorectal cancer (CRC), with adequate bowel cleansing being essential for mucosal visualisation.1 Our team previously developed an AIA tool capable of real-time evaluation of rectal effluent...
Journal IF-equivalent: 3.5 (OpenAlex 2-year mean citedness, value as of 2026-11-11, retrieved 2026-11-12; not the official Clarivate IF)Reference: [No authors listed]. Artificial intelligence-tailored bowel preparation reduces laxative burden and promotes sustainable endoscopy. Gut. [Epub ahead of print]. doi:.Checked: Abstract only - Abstract
PURPOSE: To develop and validate an artificial intelligence-enabled platform that combines efficient screening with explicit eligibility logic by converting unstructured cancer trial criteria into reusable structured queries, and illustrates potential eligibility using synthetic patients. METHODS: We downloaded actively recruiting US interventional treatment trials for advanced/metastatic breast cancer, colon cancer, and non-small cell lung cancer from ClinicalTrials.gov. Medical oncologists created 24 synthetic patient vignettes. A large language model converted trial eligibility criteria into Structured Query Language (SQL) code and patient information into structured records, enabling rule-based matching without further LLM inference. Cancer details and treatment history were considered, but not laboratory results or comorbidities. Validation included physician editing of generated eligibility code for 30 trials and independent assessments by two physicians, followed by consensus adjudication, for eligibility across ten trials. We descriptively summarized potential eligibility by trial characteristics and when varying age, ECOG performance status, sex, and ZIP code. RESULTS: Of 833 candidate trials, 746 met inclusion criteria. Performing matching for all 746 trials took a median of 0.459 seconds per patient, excluding patient-data preparation. Against physician consensus, automated matching agreed on 230/240 patient-trial pairs (95.8%; sensitivity 83.3%, specificity 100%). Across synthetic patients, potentially eligible trials ranged from 10 to 258 without geographic restrictions. Counts decreased with worse performance status and geographic restriction and were relatively stable across ages 30-90. Later-phase, randomized, and molecularly selective trials generally matched fewer vignettes. CONCLUSION: LLM-generated SQL enables rapid, explicit rule-based screening for potential trial eligibility. Evaluation in synthetic vignettes supports feasibility, while missed matches underscore the need for further validation.
Journal IF-equivalent: 4.4 (OpenAlex 2-year mean citedness, value as of 2026-11-11, retrieved 2026-11-12; not the official Clarivate IF)Reference: Goel K, Myall NJ, Dickerson J, Caswell-Jin JL, Johnson T, Worth JE, et al. Quantifying cancer clinical trial eligibility using artificial Intelligence-Based matching. JNCI Cancer Spectrum. 2026 Nov 10 [Epub ahead of print]. doi:10.1093/jncics/pkag120.Checked: Abstract only